Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 394

1.

Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.

Robson M, Svahn T, McCormick B, Borgen P, Hudis CA, Norton L, Offit K.

Cancer. 2005 Jan 1;103(1):44-51.

2.

Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?

Garcia-Etienne CA, Barile M, Gentilini OD, Botteri E, Rotmensz N, Sagona A, Farante G, Galimberti V, Luini A, Veronesi P, Bonanni B.

Ann Surg Oncol. 2009 Dec;16(12):3380-7. doi: 10.1245/s10434-009-0638-7.

PMID:
19649554
3.

Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.

Contant CM, Menke-Pluijmers MB, Seynaeve C, Meijers-Heijboer EJ, Klijn JG, Verhoog LC, Tjong Joe Wai R, Eggermont AM, van Geel AN.

Eur J Surg Oncol. 2002 Sep;28(6):627-32.

PMID:
12359199
4.

Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.

Adem C, Reynolds C, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ, Schaid DJ, Myers JL, Sellers TA, Hartmann LC, Jenkins RB.

Cancer. 2003 Jan 1;97(1):1-11.

5.

Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.

Robson M, Levin D, Federici M, Satagopan J, Bogolminy F, Heerdt A, Borgen P, McCormick B, Hudis C, Norton L, Boyd J, Offit K.

J Natl Cancer Inst. 1999 Dec 15;91(24):2112-7.

PMID:
10601383
6.
7.

Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.

J Clin Oncol. 2003 May 1;21(9):1675-81.

PMID:
12721241
8.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

9.

The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.

Golshan M, Miron A, Nixon AJ, Garber JE, Cash EP, Iglehart JD, Harris JR, Wong JS.

Am J Surg. 2006 Jul;192(1):58-62.

PMID:
16769276
10.

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.

Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD.

Breast Cancer Res. 2004;6(1):R8-R17. Epub 2003 Oct 24.

11.

Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.

Seynaeve C, Verhoog LC, van de Bosch LM, van Geel AN, Menke-Pluymers M, Meijers-Heijboer EJ, van den Ouweland AM, Wagner A, Creutzberg CL, Niermeijer MF, Klijn JG, Brekelmans CT.

Eur J Cancer. 2004 May;40(8):1150-8.

PMID:
15110878
12.
13.

The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.

Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ.

Cancer. 1998 Dec 1;83(11):2335-45.

PMID:
9840533
14.

Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.

Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

J Clin Oncol. 2008 Mar 1;26(7):1093-7. doi: 10.1200/JCO.2007.12.6078. Epub 2008 Jan 14.

PMID:
18195327
15.

Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma.

Kroman N, Holtveg H, Wohlfahrt J, Jensen MB, Mouridsen HT, Blichert-Toft M, Melbye M.

Cancer. 2004 Feb 15;100(4):688-93.

16.

Improving local control with breast-conserving therapy: a 27-year single-institution experience.

Cabioglu N, Hunt KK, Buchholz TA, Mirza N, Singletary SE, Kuerer HM, Babiera GV, Ames FC, Sahin AA, Meric-Bernstam F.

Cancer. 2005 Jul 1;104(1):20-9.

17.

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.

Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R.

Cancer. 2005 Dec 15;104(12):2807-16.

18.

Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.

Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, Menard C, Lippman ME, Lichter AS, Altemus RM.

Cancer. 2003 Aug 15;98(4):697-702.

19.

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.

Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, This P, Asselain B, Stoppa-Lyonnet D, Fourquet A.

Breast Cancer Res Treat. 2010 Feb;120(1):119-26. doi: 10.1007/s10549-009-0685-6. Epub 2009 Dec 24. Review.

PMID:
20033769
20.

Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.

Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A; Institut Curie Breast Cancer Study Group.

Eur J Cancer. 2005 Oct;41(15):2304-11. Epub 2005 Sep 1.

PMID:
16140006

Supplemental Content

Support Center